Singh Shawn has filed 5 insider transactions across 1 company since December 2023.
Most recent transaction: a grant/award of 7541 shares of Vistagen Therapeutics, Inc. ($VTGN) on June 30, 2025.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| June 30, 2025 | Vistagen Therapeutics, Inc. | $VTGN | Singh Shawn | President and CEO | A | Common Stock | 7541 | $1.70 | 38,903.0000 | 29,157,733 | 24.05% | 0.03% |
| June 23, 2025 | Vistagen Therapeutics, Inc. | $VTGN | Singh Shawn | President and CEO | A | Stock Option (Right to Buy) | 300000 | $0.00 | 300,000.0000 | 29,157,733 | 9999.99% | 1.03% |
| June 28, 2024 | Vistagen Therapeutics, Inc. | $VTGN | Singh Shawn | CHIEF EXECUTIVE OFFICER | A | Common Stock | 4854 | $2.96 | 31,362.0000 | 19,354,500 | 18.31% | 0.03% |
| June 24, 2024 | Vistagen Therapeutics, Inc. | $VTGN | Singh Shawn | CHIEF EXECUTIVE OFFICER | A | Stock Option (Right to Buy) | 500000 | $0.00 | 500,000.0000 | 19,354,500 | 9999.99% | 2.58% |
| Dec. 29, 2023 | Vistagen Therapeutics, Inc. | $VTGN | Singh Shawn | CHIEF EXECUTIVE OFFICER | A | Common Stock | 167 | $1.72 | 26,508.0000 | 0 | 0.63% | 0.00% |